For patients with metabolic syndrome and type 2 diabetes mellitus, agonists of imidazoline receptors are suitable too, especially for their stimulation of insulin secretion, decrease of sympathetic hyperactivity, and inhibition of kidney sodium reabsorption [9, 10]. The gene discussed is INS; the disease is diabetes mellitus.